2 hrs ago
Eli Lilly and Given New $60.00 Price Target at Morgan Stanley
Morgan Stanley's price objective would suggest a potential downside of 1.12% from the stock's previous close.
5 hrs ago
FDA approves JardianceA (empagliflozin) tablets for adults with type 2 diabetes
JARDIANCE is not for people with type 1 diabetes or for people with diabetic ketoacidosis .
14 hrs ago
FDA approves Lilly, Boehringer diabetes drug
Federal regulators have approved a new treatment from U.S. drugmaker Eli Lilly and Co.
18 hrs ago
Ex-Eli Lilly and Company Scientists Fighting Fraud Charges Now Battle ...
Eli Lilly is locked in a battle over the release of hundreds of thousands of pages of internal documents with two of its former scientists, who were charged earlier this year with wire fraud for allegedly leaking proprietary information about experimental drugs and providing the data to a Chinese drug maker.
Thu Jul 31, 2014
The Global and China Insulin Market is Expected to Grow at a CAGR of...
MarketResearchreports.biz presents this most up-to-date research on Global and China Insulin Market - Industry Analysis, Size, Share, Growth, Trends and Forecast , 2013 - 2019: Market Size, Trends, and Forecasts Research Report.
Wed Jul 30, 2014
Insider Selling: Eli Lilly and major shareholder Sells 250,000 Shares of Stock
Eli Lilly and major shareholder Lilly Endowment Inc sold 250,000 shares of Eli Lilly and stock in a transaction dated Tuesday, July 29th.
Court Report -- Part II - July 2014 #2
Acorda Therapeutics Inc. v. Actavis Laboratories FL Inc. 1:14-cv-00882; filed July 7, 2014 in the District Court of Delaware Infringement of U.S. Patent Nos.
Ligand: Pipeline Breakdown Reveals Bullish Outlook
With more than 90 shots on goal and several revenue driving opportunities in 2014 alone, investors should watch it very closely.
Tue Jul 29, 2014
The Indianapolis Star
Lilly fighting subpoena seeking internal documents
Lilly fighting subpoena seeking internal documents Former Lilly scientists seeking info in their defense against charges they leaked company secrets Check out this story on IndyStar.com: http://indy.st/1mZ9QKw Eli Lilly and Co.
Big Pharmas Such As Eli Lilly and Company, Johnson & Johnson, Pfizer...
Accelerator Corporation Secures $51.1 Million to Support Emerging Biotechnology Research Opportunities in New York City and Seattle Accelerator IV to Bridge Funding Gap for Early Research;Includes New Strategic Investors Eli Lilly and Company, Harris & Harris Group, Inc., Johnson & Johnson Development Corporation, The Partnership Fund for New York ... (more)
Mon Jul 28, 2014
Wall Street Journal
Wanted: Startups in Biotech
The East Side towers of the Alexandria Center for Life Science have attracted giant pharmaceutical companies such as Pfizer Inc. and Eli Lilly & Co.
The San Diego Union-Tribune
NewsUCSD raises $1.1 billion for research
UC San Diego raised almost $1.1 billion for research over the past year, maintaining the school's standing as one of the nation's 10 largest centers for science, engineering and medicine.
Expect Gilead Sciences To Outperform
Based on comparable valuations for the industry, the stock is considerably undervalued.
Sat Jul 26, 2014
Eli Lilly and Receives Neutral Rating from Zacks
's stock had its "neutral" rating restated by Zacks in a report released on Friday.
Fri Jul 25, 2014
Behning's Corporate School Money Still Flowing
Pass this article on to your neighbors, your community members and leaders and to the people in Lockhart's district, many of them in Indianapolis.
The Miami Herald
Lilly 2Q profit falls 39 percent
Eli Lilly and Co. on Thursday reported profit that declined by 39 percent in its second quarter, and beat analysts' expectations.
Thu Jul 24, 2014
Covance deal not that simple
While city officials are supportive of drawing roughly 360 acres of the Covance campus into city limits, it's still unclear how tax breaks on the deal would work.
Eli Lilly and Company Reports Second-Quarter 2014 Results
Second-quarter 2014 revenue declined 17 percent driven by the impact of U.S. patent expirations for Cymbalta and Evista, partially offset by volume growth in several other products.
Loss of Patents Main Cause of Lower Earnings at Eli Lilly and Co
The loss of Patents over the years, has been the main cause of lower earnings at Eli Lilly and Co , the CEO of the company, Dr. John Lechleiter, said in an interview on CNBC .